Rapid Phenotypic Assays for Antimicrobial Susceptibility Testing

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Rapid phenotypic antimicrobial susceptibility testing (AST) compresses turnaround time through accelerated growth detection, direct-from-specimen processing, or immunodetection of expressed resistance markers while preserving measurement of actual organism response to antibiotics.
• Evaluate candidate systems against your laboratory's specimen types, organism coverage, workflow integration needs, and validation evidence, using CLSI standards as the reference framework for performance comparison.
• Key limitation: many rapid AST technologies remain in early development or have limited clinical validation, so conventional culture-based methods still anchor definitive susceptibility reporting.

At a Glance

The Clinical Problem: Turnaround Time in Susceptibility Testing

Antimicrobial resistance is a global public-health priority because resistant infections complicate treatment, increase morbidity, and drive the need for stewardship programs that preserve effective antibiotics. The World Health Organization defines antimicrobial resistance as the ability of microorganisms to withstand antimicrobial treatments that were previously effective, and it coordinates surveillance and stewardship efforts across countries and health systems. Within this context, clinical microbiology laboratories carry a central responsibility: they must tell clinicians which antibiotics will work against a patient's infection, and they must do so quickly enough to influence therapy decisions.

Conventional phenotypic AST follows a well-established workflow. A clinical specimen is cultured to isolate the pathogen, the organism is identified, and then it is exposed to a panel of antibiotics at defined concentrations. Growth or inhibition is read after an incubation period, typically 16 to 24 hours. The result is reported as a minimum inhibitory concentration (MIC), the lowest antibiotic concentration that prevents visible growth, or as a categorical interpretation such as susceptible, intermediate, or resistant. The Clinical and Laboratory Standards Institute (CLSI) publishes the standards that define how these tests should be performed, how results should be interpreted, and what quality-control measures are required. These standards are the backbone of reproducible susceptibility testing in clinical laboratories.

The problem is time. For a patient with sepsis, the interval between specimen collection and an actionable susceptibility result can exceed 48 hours because blood culture alone requires one to two days before sufficient organism growth is available for testing. During that window, clinicians must choose antibiotics empirically, often using broad-spectrum agents that may be unnecessary, ineffective, or both. The consequences include delayed appropriate therapy, increased selective pressure for resistance, and prolonged hospital stays. Rapid phenotypic AST methods aim to compress this timeline while preserving the fundamental advantage of phenotypic testing: it measures what the organism actually does in the presence of the drug, instead of inferring resistance from genetic markers alone.

Core Principles of Rapid Phenotypic AST

Phenotypic AST measures the observable response of a living organism to an antimicrobial agent. This distinguishes it from genotypic methods, which detect resistance genes or mutations. Phenotypic results capture the net effect of all resistance mechanisms operating in a given isolate, including those that are not yet characterized at the genetic level. Rapid phenotypic AST retains this principle but changes how growth is detected, how the inoculum is prepared, or how the test is read.

Growth Detection as the Rate-Limiting Step

Conventional AST relies on visible turbidity or colony formation as the endpoint. Visible growth requires a certain number of cell divisions, which sets a floor on incubation time. Rapid systems replace visual detection with more sensitive physical or chemical measurements. Optical density monitoring, fluorescence, electrochemical impedance, and microcalorimetry can all detect small changes in bacterial mass or metabolic activity long before turbidity becomes visible. A review of next-generation rapid AST technologies characterized over ninety distinct systems and found that the field is defined by innovations in how growth is monitored, how quickly organisms are recovered from specimens, and how test results are read. The common thread is that these systems detect the earliest signs of bacterial replication under antibiotic pressure.

Inoculum Preparation and Direct-from-Specimen Testing

A second rate-limiting step is the need for a pure, standardized inoculum. Conventional workflows require subculture from a positive blood culture bottle or from a primary isolation plate. Rapid systems attempt to shorten or eliminate this step. Some commercial systems accept positive blood culture broth directly and use short incubation protocols to generate susceptibility results within hours. Others go further and attempt to recover pathogens directly from whole blood, bypassing blood culture entirely. One research platform used a synthetic peptide to selectively capture a broad range of bacterial pathogens from whole blood, then performed species identification and phenotypic susceptibility testing on a low-inoculum chip. In a clinical evaluation of 190 hospitalized patients, the platform achieved 100% agreement in species identification and, among eight positive cases, an overall categorical agreement of 94.90% for susceptibility testing, with an average theoretical turnaround time of 13 ± 2.53 hours from initial blood processing. This approach demonstrates the potential to reduce reporting time by 40 to 60 hours compared with hospital AST workflows, but it also illustrates the validation burden required before such systems enter routine use.

Immunodetection of Resistance Markers

A distinct category of rapid phenotypic tests uses antibodies to detect specific resistance proteins or modified bacterial targets. These tests are phenotypic in the sense that they detect the expressed product of a resistance mechanism instead of the gene that encodes it. For example, immunodetection of carbapenemase enzymes can identify the mechanism responsible for carbapenem resistance in Enterobacterales. These assays are fast, often producing results in under an hour, and they are simple to perform. Their limitation is specificity: they detect only the resistance mechanisms for which antibodies exist, and they do not provide an MIC. They answer a focused question, such as whether a carbapenemase is present, instead of the broader question of which antibiotics will work. They are best understood as complementary tools within a rapid AST program, not as replacements for quantitative susceptibility testing.

The Regulatory and Standards Landscape

CLSI Standards as the Reference Framework

The Clinical and Laboratory Standards Institute publishes the consensus standards that define acceptable performance for antimicrobial susceptibility testing. These documents cover test methods, quality control, interpretive criteria, and reporting practices. For any rapid phenotypic AST system, the relevant question is whether its results agree with the reference methods described in CLSI standards. Categorical agreement, essential agreement, and error rates are calculated against these reference methods during validation. Laboratories that adopt rapid systems must verify that the system performs acceptably in their own setting before reporting patient results. CLSI standards also define the quality-control organisms and acceptable ranges that must be used to monitor ongoing test performance.

EUCAST and International Harmonization

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) operates as an international committee organized by the European Society for Clinical Microbiology and Infectious Diseases and functions as the breakpoint advisory committee of the European Medicines Agency. EUCAST harmonizes clinical breakpoints across Europe and has developed its own disk diffusion method and rapid AST protocols directly from blood culture bottles. The committee maintains large collections of MIC distributions, defines epidemiological cutoff values (ECOFFs), and publishes expert rules for resistance mechanism detection. EUCAST recently revised the definitions of the clinical interpretive categories S, I, and R, which affects how susceptibility results are categorized and reported. Laboratories operating outside Europe may still encounter EUCAST breakpoints in the literature and in multicenter studies, so understanding both CLSI and EUCAST frameworks is necessary for interpreting published validation data on rapid AST systems.

Regulatory Pathways and Validation Milestones

Rapid AST systems intended for clinical use must obtain regulatory clearance before they can be marketed for patient testing. The review of next-generation rapid AST technologies examined publications and regulatory submissions to characterize the development pipeline, including technology readiness level and extent of clinical validation. This analysis found that the field spans a wide range of maturity, from research prototypes to commercially available systems with regulatory approval. For laboratory professionals, the practical implication is that published performance data must be read carefully. A system described in a research publication may have been evaluated on a small number of isolates, under idealized conditions, or with reference methods that do not match the laboratory's own workflow. Regulatory submissions provide a more standardized evidence base, but the details of the intended use, specimen types, and organism coverage must be reviewed against the laboratory's needs.

Practical Workflow for Evaluating Rapid Phenotypic AST Systems

Laboratories considering adoption of a rapid phenotypic AST system should follow a structured evaluation process. The goal is to determine whether the system meets the laboratory's clinical needs, fits its workflow, and performs acceptably in its hands.

Step 1: Define the Clinical Need

Start by identifying the specific problem the rapid system is meant to solve. Is the goal to reduce time to optimal therapy for patients with positive blood cultures? Is it to provide rapid detection of specific resistance mechanisms for infection-control purposes? Is it to support antimicrobial stewardship by enabling earlier de-escalation from broad-spectrum agents? The answers determine which system characteristics matter most. A laboratory serving a hospital with a high volume of bloodstream infections may prioritize direct-from-blood-culture systems with short turnaround times. A laboratory supporting an outpatient setting may have less urgent needs and may prioritize simplicity and cost. The World Health Organization emphasizes that antimicrobial resistance surveillance and stewardship require laboratory capacity that is appropriate to the setting, and the same principle applies to technology selection.

Step 2: Review the Evidence Base

For each candidate system, assemble the available evidence. This includes peer-reviewed publications, regulatory submissions, manufacturer validation data, and independent evaluations. Pay attention to the following elements:

• Organism coverage: Which species were included in the validation? Does the panel match the laboratory's typical isolate distribution?
• Specimen types: Was the system validated on the specimen types the laboratory will test, such as positive blood culture broth, urine, or direct specimens?
• Reference method: What was the comparator? CLSI broth microdilution is the preferred reference for most systems.
• Performance metrics: Categorical agreement, essential agreement, major error rate, and very major error rate should be reported. The review of next-generation rapid AST technologies noted that the extent of clinical validation varies widely across systems, so these metrics may not be available for all products.
• Time-to-result: How is turnaround time defined? Does it include specimen processing, or only the assay incubation?
• Limitations: What does the manufacturer list as limitations? Are there known interference issues, organism exclusions, or drug classes that cannot be tested?

Step 3: Assess Workflow Integration

A rapid AST system that requires extensive manual steps, specialized training, or equipment that does not fit the laboratory's physical layout will not deliver its promised turnaround time in practice. Map the proposed workflow from specimen receipt to result reporting. Identify where the rapid system fits. Does it replace an existing test, or does it add a new step? How will results be transmitted to the electronic health record? Who will perform the test on all shifts? The American Society for Microbiology provides professional education and practice resources that address laboratory workflow and workforce considerations, and these resources can help laboratories plan for the operational changes that accompany new technology adoption.

Step 4: Conduct a Verification Study

Before reporting patient results, the laboratory must verify that the system performs as expected in its own setting. This verification typically includes testing a panel of well-characterized organisms, including quality-control strains from a culture collection such as the American Type Culture Collection (ATCC), and comparing results to the reference method. The verification panel should include organisms with known resistance mechanisms, organisms at the breakpoint boundaries, and organisms representing the range of species the laboratory expects to test. The verification study should be designed according to CLSI guidelines, and the results should be reviewed by the laboratory director before the system is placed into routine service.

Step 5: Establish Ongoing Quality Control

Rapid systems require the same quality-control discipline as conventional methods. This includes daily or per-run testing of quality-control organisms, monitoring of performance over time, and participation in external quality assessment programs where available. The Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidance from CDC and NIH provides the framework for safe handling of the organisms used in these tests, including the risk assessment that should accompany any new procedure. Quality-control failures must be documented and investigated, and the laboratory must have a defined process for escalating problems to the manufacturer and to the laboratory director.

Options and Tradeoffs Among Rapid AST Approaches

Accelerated Broth Dilution Systems

Accelerated broth dilution systems miniaturize or optimize the conventional broth microdilution format. They use small volumes, sensitive detection optics, and short incubation protocols to generate MICs in a few hours instead of overnight. These systems have the advantage of producing quantitative MIC results that map directly to CLSI or EUCAST interpretive categories. They are best suited to laboratories that need full susceptibility panels for a moderate volume of isolates. The tradeoff is that they still require a pure culture or positive blood culture broth as the starting material, so they do not eliminate the culture step entirely.

Direct-from-Specimen Systems

Direct-from-specimen systems attempt to recover pathogens from the clinical specimen itself, most commonly whole blood, and perform susceptibility testing without prior culture. The research platform described earlier used a synthetic peptide to capture pathogens from whole blood, followed by identification and low-inoculum AST. This approach has the potential to reduce turnaround time by days, but it faces substantial technical challenges. The number of organisms in blood during bacteremia is often very low, which makes recovery and detection difficult. The system must also distinguish true pathogens from contaminants and handle mixed infections. Clinical validation is at an early stage, and the 94.90% categorical agreement observed in one study, while promising, was based on a small number of positive cases. Laboratories considering this category should recognize that it is the least mature and the most dependent on continued technical refinement.

Immunodetection of Resistance Markers

Immunodetection assays answer focused questions about specific resistance mechanisms. They are rapid, simple, and inexpensive compared with full AST systems. Their role in the laboratory is to provide actionable information while a full susceptibility panel is in progress. For example, a positive carbapenemase immunodetection result can trigger infection-control precautions and guide early therapy choices before the complete AST result is available. The tradeoff is that these assays do not provide MICs and cannot detect resistance mechanisms outside their antibody panel. They are adjuncts to, not replacements for, quantitative susceptibility testing.

Molecular and Genotypic Methods as Context

Although this article focuses on phenotypic methods, genotypic approaches are part of the rapid testing landscape. Whole-genome sequencing and targeted molecular assays can detect resistance genes directly from specimens or from cultured isolates. The NCBI Pathogen Detection resource aggregates genomic data from foodborne and healthcare-associated pathogens to support surveillance and outbreak detection. Genotypic methods are fast and can be highly specific, but they infer resistance from the presence of genes instead of measuring the organism's actual response to the drug. Phenotypic methods remain necessary to confirm resistance, to detect novel mechanisms, and to provide MICs for therapy selection. The relationship between phenotypic and genotypic resistance is an active area of study, and EUCAST has an ad hoc subcommittee examining this relationship to inform future breakpoint and expert-rule decisions.

Records and Measurements for Rapid AST Programs

Laboratories implementing rapid phenotypic AST must maintain records that document performance, quality control, and clinical impact. These records serve multiple purposes: they satisfy regulatory and accreditation requirements, they support troubleshooting when problems arise, and they provide the data needed to evaluate whether the rapid system is achieving its intended clinical benefit.

Required Records

• Verification study documentation, including the panel of organisms tested, the reference method used, and the calculated performance metrics
• Daily quality-control results for each lot of test panels or reagents
• Instrument maintenance and calibration records
• Operator training and competency assessment records
• External quality assessment or proficiency testing results
• Incident reports for quality-control failures, instrument malfunctions, or discrepant results

Measurements That Matter

Using Records for Program Improvement

Records should be reviewed periodically to identify trends. A rising very major error rate for a specific drug-organism combination may indicate a problem with the test panel, the quality-control organisms, or the interpretation algorithm. An increase in turnaround time may indicate workflow bottlenecks or staffing issues. The World Health Organization's antimicrobial resistance surveillance framework emphasizes that laboratory data are only useful when they are analyzed and acted upon, and the same principle applies at the individual laboratory level. Regular review of rapid AST program data supports continuous quality improvement and provides the evidence needed to justify the continued use of the system.

Common Failure Patterns and Troubleshooting

Failure Pattern 1: Inoculum Density Errors

Rapid AST systems are sensitive to inoculum density because they detect growth at very early time points. An inoculum that is too heavy can produce false resistance, while an inoculum that is too light can produce false susceptibility. This is a particular risk with direct-from-specimen systems, where the number of organisms in the specimen is variable and cannot be standardized by conventional methods. Laboratories should follow the manufacturer's instructions for inoculum preparation exactly, verify that the system's internal inoculum checks are functioning, and investigate any results that are inconsistent with the organism's expected susceptibility profile.

Failure Pattern 2: Detection of Contaminants or Mixed Cultures

Rapid systems that work directly from blood culture broth or clinical specimens may detect organisms that are not the true pathogen. Blood cultures can contain skin flora contaminants, and mixed infections can produce susceptibility results that reflect the combined population instead of a single organism. The clinical evaluation of the direct-from-blood system described earlier achieved 100% agreement in species identification, but this level of performance may not be reproducible in all settings. Laboratories must have a process for correlating rapid AST results with the Gram stain, culture morphology, and identification results, and they must be prepared to repeat testing when discrepancies arise.

Failure Pattern 3: Antibiotic Panel Gaps

Rapid systems may not test the full range of antibiotics that the laboratory's clinicians expect. Some systems test a limited panel optimized for speed, while others exclude drug classes that are difficult to test in the rapid format. This can create workflow problems when clinicians request antibiotics that are not on the rapid panel, requiring a follow-up conventional test and negating the turnaround-time advantage. Laboratories should review the antibiotic panels of candidate systems against their local antibiogram and prescribing patterns before adoption.

Failure Pattern 4: Interpretation Discrepancies at Breakpoints

Organisms with MICs near the clinical breakpoint are the most difficult to categorize correctly, and they are the source of most major and very major errors. Rapid systems may have particular difficulty with these organisms because early growth detection can be affected by subtle differences in growth kinetics. Laboratories should pay close attention to the performance of rapid systems for organisms with MICs near breakpoints, and they should consider confirmatory testing when a rapid result falls in a category that is inconsistent with the organism's typical resistance profile.

Failure Pattern 5: Quality-Control Failures

Quality-control failures in rapid AST systems can be caused by degraded reagents, improper storage, instrument malfunction, or operator error. The laboratory must have a defined process for responding to quality-control failures, including repeating the test, documenting the failure, and notifying the manufacturer if the problem persists. The BMBL guidance provides the framework for the biosafety practices that should accompany all laboratory procedures, including the handling of quality-control organisms and the decontamination of spills.

Biosafety and Laboratory Safety Considerations

Rapid phenotypic AST systems involve the manipulation of viable microorganisms, including organisms that may be highly resistant to antibiotics. The Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidance from CDC and NIH provides the foundational framework for risk assessment, containment, and decontamination in laboratories that handle infectious agents. Laboratories implementing rapid AST systems must conduct a risk assessment that considers the organisms being tested, the procedures being performed, and the potential for aerosol generation or splashes.

Most clinical microbiology laboratories operate at Biosafety Level 2 (BSL-2), which requires restricted access, trained personnel, and standard precautions including hand washing, personal protective equipment, and decontamination of work surfaces. Rapid AST systems that process positive blood culture bottles or direct clinical specimens may generate aerosols during specimen handling, and these procedures should be performed in a biological safety cabinet where indicated. The BMBL guidance also addresses the safe handling of sharps, the management of spills, and the decontamination of infectious waste.

Laboratories should also consider the specific risks associated with testing highly resistant organisms. Organisms such as carbapenem-resistant Enterobacterales, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant enterococci require the same biosafety practices as other clinical isolates, but the consequences of laboratory-acquired infection may be more serious. The risk assessment should include a review of the laboratory's occupational health program, including vaccination recommendations and post-exposure protocols.

Professional Escalation Criteria

Laboratory professionals should know when to escalate concerns about rapid AST systems to supervisors, the laboratory director, the manufacturer, or regulatory authorities. The following situations warrant escalation:

• A rapid AST result that is clinically discrepant with the patient's response to therapy, particularly if the result suggests susceptibility to an antibiotic that is not working
• A very major error, where the rapid system reports an organism as susceptible but the reference method reports it as resistant
• A quality-control failure that cannot be resolved after repeat testing
• An instrument malfunction that affects patient results
• A pattern of discrepant results that suggests a systemic problem with the test system
• Any result that raises concern about a novel resistance mechanism or an unusual organism

The laboratory director is responsible for the final decision to report or withhold patient results, and the director should be involved in any investigation of discrepant results. The manufacturer should be notified of systemic problems, and regulatory authorities should be notified if the problem suggests a defect in a cleared device. The American Society for Microbiology provides professional resources and forums where laboratory professionals can discuss challenging cases and share experiences with new technologies.

Limitations of Rapid Phenotypic AST

Validation Gaps

The most significant limitation of rapid phenotypic AST is the variable extent of clinical validation across systems. The review of next-generation rapid AST technologies found that the field includes systems at widely different stages of development, from research prototypes to commercially available products with regulatory clearance. Published performance data may be based on small isolate collections, single-center studies, or retrospective analyses. Laboratories must critically appraise the evidence for each system and recognize that published performance may not predict performance in their own setting.

Organism and Specimen Limitations

Rapid systems are not universal. Each system has defined organism coverage, and organisms outside that coverage must be tested by conventional methods. Some systems are validated only for specific specimen types, such as positive blood culture broth, and cannot be used for urine, respiratory, or wound specimens. The direct-from-blood approach, while promising, has been evaluated in a limited number of clinical cases, and its performance in routine practice is not yet established.

Cost and Resource Requirements

Rapid AST systems are generally more expensive per test than conventional methods, and they may require specialized equipment, reagents, and training. The cost-benefit analysis must consider the direct cost of the test and the potential savings from reduced length of stay, earlier appropriate therapy, and improved antimicrobial stewardship. For laboratories in low-resource settings, the review of next-generation rapid AST technologies noted that conventional clinical bacteriology has been slow to implement, and the cost and infrastructure requirements of rapid systems may be prohibitive. The World Health Organization's antimicrobial resistance program emphasizes the need for laboratory capacity building that is appropriate to local resources, and this principle applies to technology selection.

The Continuing Role of Conventional AST

Rapid phenotypic AST does not replace conventional AST. Conventional methods remain the reference standard for susceptibility testing, and they are required for organisms, drug classes, and specimen types that are not covered by rapid systems. Rapid systems provide earlier actionable information, but they must be integrated into a workflow that includes conventional testing for confirmation and for full susceptibility panels. The EUCAST Development Laboratory has played a critical role in developing rapid AST methods directly from blood culture bottles, but it continues to maintain and refine conventional methods as the foundation of susceptibility testing.

The Future of Rapid Phenotypic AST

The field of rapid phenotypic AST is evolving rapidly, driven by clinical need, technological innovation, and regulatory interest. The review of next-generation rapid AST technologies characterized over ninety systems and identified the technical innovations, technology readiness levels, and validation milestones that define the current landscape. Several trends are likely to shape the field in the coming years.

Integration with Identification

Rapid AST systems are increasingly being combined with rapid identification methods, so that a single platform can provide both species identification and susceptibility results from the same specimen or culture. This integration reduces the total time to actionable information and simplifies the laboratory workflow. The direct-from-blood platform described earlier combined species identification with phenotypic AST, and this integrated approach is likely to become more common.

Expansion of Organism Coverage

Current rapid systems focus primarily on the most common bloodstream pathogens, including Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa. Future systems are likely to expand coverage to include anaerobes, fungi, and mycobacteria. EUCAST has established subcommittees for antifungal susceptibility testing (AFST) and antimicrobial susceptibility testing of mycobacteria (AMST), reflecting the clinical need for rapid testing in these areas.

Improved Correlation with Clinical Outcomes

The ultimate measure of a rapid AST system is whether it improves patient outcomes. Future validation studies are likely to include clinical outcome measures, such as time to optimal therapy, length of stay, and mortality, in addition to traditional performance metrics. The World Health Organization's antimicrobial resistance surveillance framework emphasizes the importance of linking laboratory data to clinical and public-health action, and this linkage will be essential for demonstrating the value of rapid AST systems.

Continued Harmonization of Standards

The coexistence of CLSI and EUCAST breakpoints creates challenges for laboratories that operate internationally or that interpret studies using different breakpoint systems. The recent EUCAST revision of the S, I, and R definitions is part of an ongoing effort to harmonize interpretive criteria, and future rapid AST systems will need to accommodate both frameworks. Laboratories should monitor these developments and be prepared to update their reporting practices as standards evolve.

Building a Cost-Per-Result Model for Rapid Phenotypic AST Selection

Laboratories evaluating rapid phenotypic AST systems often compare list prices or per-test reagent costs, but these figures do not capture the true financial impact of a new testing platform. A cost-per-result model that accounts for the full workflow, including labor, repeat testing, instrument amortization, and the clinical consequences of delayed or inaccurate results, provides a more reliable basis for technology selection. This model is distinct from a simple budget review because it forces the laboratory to quantify how the rapid system changes its entire testing process, beyond the cost of one consumable.

Defining the Cost Components

The first step in building a cost-per-result model is to identify every cost component that changes when a rapid AST system is introduced. These components fall into four categories: direct consumables, labor, infrastructure, and downstream clinical costs.

Direct consumables include the test cartridge or panel, reagents, quality-control materials, and any specimen-processing supplies that are specific to the rapid system. These costs are usually well documented by the manufacturer, but they must be calculated per reportable result, not per test performed. If the system requires repeat testing for a percentage of specimens, the consumable cost per reportable result increases accordingly.

Labor costs are often the largest variable and the most frequently underestimated. Calculate the hands-on time required per specimen for each step of the rapid workflow, including specimen receipt, processing, instrument loading, result review, and reporting. Multiply this time by the fully loaded labor rate for the personnel who will perform the test. The American Society for Microbiology provides professional education resources that address workforce planning and competency assessment, and these resources can help laboratories estimate the training time and skill level required for new testing platforms.

Infrastructure costs include instrument purchase or lease, maintenance contracts, calibration, and the physical space required for the instrument. These costs should be amortized over the expected instrument lifespan and divided by the projected annual test volume. A system that requires dedicated bench space in a crowded laboratory may also incur indirect costs for laboratory redesign or workflow disruption.

Downstream clinical costs are the most difficult to quantify but often the most important. These include the cost of additional days of broad-spectrum antibiotic therapy while waiting for conventional AST results, the cost of isolation precautions for patients with resistant organisms, and the cost of treating adverse outcomes from inappropriate therapy. The World Health Organization emphasizes that antimicrobial resistance drives increased healthcare costs through longer hospital stays and the need for more expensive second-line drugs, and these costs should be included in any comprehensive evaluation of rapid AST systems.

Calculating the Cost per Reportable Result

The cost per reportable result is calculated by summing all costs attributable to the rapid AST system over a defined period and dividing by the number of results actually reported to clinicians during that period. This calculation must include the costs of failed tests, repeat testing, and quality-control failures, because these events consume resources without producing a reportable result.

For example, consider a laboratory that performs 100 rapid AST tests per month. The direct consumable cost is 50 dollars per test, the labor cost is 15 dollars per test, and the amortized infrastructure cost is 10 dollars per test. The total direct cost is 75 dollars per test, or 7,500 dollars per month. If 5 percent of tests fail and require repeat testing, the laboratory performs 105 tests to obtain 100 reportable results, increasing the cost per reportable result to 78.75 dollars. If the rapid system reduces the time to optimal therapy by 24 hours for 80 percent of patients, and the hospital estimates that each day of broad-spectrum therapy costs 200 dollars in drug and nursing costs, the downstream savings are 16,000 dollars per month, far exceeding the direct cost of the rapid system.

This example illustrates why the cost-per-result model must include downstream clinical costs. A rapid system that appears expensive on a per-test basis may be highly cost-effective when it reduces hospital days or prevents adverse outcomes. Conversely, a system with a low per-test cost may be a poor investment if it does not integrate with the laboratory workflow or if its results are not trusted by clinicians, leading to confirmatory testing that negates the turnaround-time advantage.

Comparing Systems with a Standardized Model

To compare multiple rapid AST systems, build the cost-per-result model for each system using identical assumptions. The assumptions should be based on the laboratory's own data where possible, including average test volume, specimen mix, personnel costs, and current turnaround times. Where local data are not available, use published estimates and clearly document the source of each assumption so that the model can be updated as better data become available.

The comparison should include a sensitivity analysis that tests how the results change when key assumptions vary. For example, what happens to the cost per reportable result if the test volume is 50 percent lower than projected? What happens if the failure rate is 10 percent instead of 5 percent? What happens if the downstream savings are only half of the initial estimate? The Clinical and Laboratory Standards Institute provides standards-based guidance for evaluating susceptibility testing methods, and this framework can be extended to the economic evaluation by ensuring that the performance assumptions in the cost model are consistent with the performance data from validation studies.

Recording Model Inputs and Updating the Model

The cost-per-result model is only useful if it is based on documented, verifiable inputs. Maintain a spreadsheet or database that records each assumption, its source, and the date it was last updated. Review the model quarterly or whenever there is a significant change in test volume, pricing, staffing, or clinical practice. The records should include the actual failure rates and repeat-testing rates observed in the laboratory, because these figures often differ from manufacturer estimates.

The Bacteriological Analytical Manual from the U.S. Food and Drug Administration provides a model for documenting method performance and quality data in a structured format, and the same discipline should apply to the economic evaluation of rapid AST systems. Laboratories should track the actual cost per reportable result over time and compare it to the model projection. Discrepancies between projected and actual costs should trigger an investigation into the cause, which may reveal workflow inefficiencies, unexpected failure rates, or changes in test volume that were not anticipated.

Common Errors in Cost Modeling

The most common error in cost modeling is omitting labor costs or underestimating hands-on time. Rapid AST systems are often marketed as automated, but they still require operator time for specimen preparation, instrument loading, and result review. Observe the actual workflow during the verification study and time each step to obtain realistic labor estimates.

A second common error is ignoring the cost of confirmatory testing. If clinicians do not trust rapid results for certain organism-drug combinations, they may order conventional AST to confirm the rapid result, doubling the testing cost. The cost model should include the expected rate of confirmatory testing based on the laboratory's reporting policies and the confidence of the medical staff.

A third error is treating the cost model as a one-time exercise. Costs change over time as test volumes fluctuate, reagent prices are renegotiated, and staffing levels change. The model should be a living document that is updated regularly and reviewed by the laboratory director and the hospital finance department.

Using the Model for Procurement Decisions

The cost-per-result model should be a central component of the procurement decision, but it should not be the only factor. The model provides the financial context for the decision, while the validation data, workflow assessment, and clinical need define whether the system is appropriate for the laboratory. The review of next-generation rapid AST technologies found that the field includes systems at widely different stages of development and with different levels of clinical validation, and the cost model should incorporate the risk that a system with limited validation may require additional verification studies or may fail to perform as expected in routine use.

Present the cost model to the hospital administration or budget committee as part of the business case for adopting a rapid AST system. The model should clearly show the projected costs, the projected savings, and the assumptions underlying both. The World Health Organization's antimicrobial resistance program emphasizes that investments in laboratory capacity must be justified by their contribution to patient care and public health, and the cost-per-result model provides the quantitative evidence needed for this justification.

Frequently Asked Questions

What is the difference between phenotypic and genotypic antimicrobial susceptibility testing?

Phenotypic AST measures the organism's observable response to an antibiotic, typically by detecting growth inhibition and reporting a minimum inhibitory concentration. Genotypic testing detects resistance genes or mutations in the organism's DNA. Phenotypic testing captures the net effect of all resistance mechanisms, including those not yet characterized genetically, while genotypic testing can be faster but may miss novel or uncharacterized resistance mechanisms.

How much faster are rapid phenotypic AST systems compared with conventional methods?

The speed advantage varies by system and workflow. Accelerated broth dilution systems can produce results in a few hours compared with 16 to 24 hours for conventional methods. Direct-from-specimen systems have demonstrated potential to reduce turnaround time by 40 to 60 hours compared with hospital AST workflows, with one clinical evaluation reporting an average theoretical turnaround time of 13 ± 2.53 hours from initial blood processing.

What is categorical agreement and why does it matter?

Categorical agreement is the percentage of rapid AST results that match the reference method when results are classified as susceptible, intermediate, or resistant. It matters because clinicians make treatment decisions based on these categories. A very major error, where a resistant organism is reported as susceptible, is the most dangerous type of error because it can lead to treatment with an ineffective antibiotic.

Can rapid phenotypic AST replace conventional susceptibility testing?

No. Rapid phenotypic AST provides earlier actionable information, but conventional methods remain the reference standard and are required for organisms, drug classes, and specimen types not covered by rapid systems. Rapid systems are best used as an adjunct to conventional testing, providing preliminary results that guide early therapy while conventional testing provides definitive results.

What quality-control measures are required for rapid AST systems?

Quality control for rapid AST systems includes daily or per-run testing of quality-control organisms with known susceptibility profiles, monitoring of performance over time, and participation in external quality assessment programs. Quality-control organisms should be obtained from authenticated culture collections, such as the American Type Culture Collection, and testing should follow CLSI guidelines.

How should a laboratory evaluate a rapid AST system before adoption?

A laboratory should define its clinical need, review the published evidence and regulatory submissions for candidate systems, assess workflow integration, conduct a verification study using well-characterized organisms, and establish ongoing quality control. The verification study should compare rapid system results to a CLSI reference method and calculate categorical agreement, essential agreement, and error rates.

What are the biosafety considerations for rapid AST systems?

Rapid AST systems involve the manipulation of viable microorganisms, including potentially highly resistant organisms. Laboratories should follow the Biosafety in Microbiological and Biomedical Laboratories guidance from CDC and NIH, which covers risk assessment, containment, decontamination, and safe handling of infectious agents. Procedures that may generate aerosols should be performed in a biological safety cabinet.

What should a laboratory do if a rapid AST result is discrepant with the reference method?

The laboratory should investigate the discrepancy, review the quality-control results, and consider repeating the test. If the discrepancy suggests a very major error, the laboratory director should be notified, and the result should not be reported until the discrepancy is resolved. Systemic problems should be reported to the manufacturer, and regulatory authorities should be notified if a device defect is suspected.

Related Bacteriology Guides

• Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
• Bacterial Infections in Poultry: Clinical Manifestations, Diagnosis, and Antimicrobial Therapy
• Swine Dysentery: Age Susceptibility, Causative Agent, and Clinical Management in Pigs
• Colibacillosis in Chickens: Pathogenesis, Clinical Signs, and Antimicrobial Treatment
• Salmonellosis in Poultry: A Comprehensive Clinical Guide

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Next-generation rapid phenotypic antimicrobial susceptibility testing.. Nature communications, 2024.
• Blood culture-free ultra-rapid antimicrobial susceptibility testing.. Nature, 2024.
• Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST).. Journal of clinical microbiology, 2022.
• Emerging technologies for rapid phenotypic antimicrobial susceptibility testing of clinical isolates of bacteria.. Journal of clinical microbiology, 2025.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.